Why the study?
Does trastuzumab treatment cause right ventricle deterioration measured by echocardiography in breast cancer patients with erb-2 overexpression?
Does trastuzumab treatment cause right ventricle deterioration measured by echocardiography in breast cancer patients with erb-2 overexpression?
Echocardiographic parameters including TAPSE, RV MPI, and E/e' ratio may serve as early markers of right ventricular toxicity from trastuzumab in breast cancer patients.
Answers are grounded in this paper and cite their sources.
Trastuzumab may associate with early RV changes on echo; hypothesis-generating and leaves open need for routine RV monitoring.
In our study; we observed a trend of RV deterioration after trastuzumab treatment. These preliminary RV changes were demonstrated by using TAPSE, RV tissue Doppler imaging derived MPI and E/e' ratio parameters by echocardiography and these parameters could also use as markers of trastuzumab toxicity in this population.
No takes yet. Share an insight, caveat, or question.
Kılıçaslan et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: